ABT-925, also known as A-437203 or as LU-201640, is a selective dopamine D3 receptor antagonist which was under development for the treatment of schizophrenia but was never marketed.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.